Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'ATYPICAL NEUROLEPTICS' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 122 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Gimenez-Roldan, S; Mateo, D; Navarro, E; Gines, MM
      Efficacy and safety of clozapine and olanzapine: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis

      PARKINSONISM & RELATED DISORDERS
    2. Moritz, S; Andresen, B; Jacobsen, D; Mersmann, K; Wilke, U; Lambert, M; Naber, D; Krausz, M
      Neuropsychological correlates of schizophrenic syndromes in patients treated with atypical neuroleptics

      EUROPEAN PSYCHIATRY
    3. Friedlander, R; Lazar, S; Klancnik, J
      Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities

      CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
    4. Fakhoury, WKH; Wright, D; Wallace, M
      Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    5. Gil, FP; Schneider, C; Grohmann, R; Ruther, E
      Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy

      NERVENARZT
    6. Grunder, G; Vernaleken, I; Benkert, O
      Which properties make a neuroleptic "atypical"?

      NERVENARZT
    7. Nopoulos, PC; Ceilley, JW; Gailis, EA; Andreasen, NC
      An MRI study of midbrain morphology in patients with schizophrenia: Relationship to psychosis, neuroleptics, and cerebellar neural circuitry

      BIOLOGICAL PSYCHIATRY
    8. Bertolino, A; Callicott, JH; Mattay, VS; Weidenhammer, KM; Rakow, R; Egan, MF; Weinberger, DR
      The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia

      BIOLOGICAL PSYCHIATRY
    9. Gallinat, J; Riedel, M; Juckel, G; Sokullu, S; Frodl, T; Moukhtieva, R; Mavrogiorgou, P; Nissle, S; Muller, N; Danker-Hopfe, H; Hegerl, U
      P300 and symptom improvement in schizophrenia

      PSYCHOPHARMACOLOGY
    10. Barnas, C; Quiner, S; Tauscher, J; Hilger, E; Willeit, M; Kufferle, B; Asenbaum, S; Brucke, T; Rao, ML; Kasper, S
      In vivo I-123 IBZM SPECT imaging of striatal dopamine 2 receptor occupancyin schizophrenic patients

      PSYCHOPHARMACOLOGY
    11. Remschmidt, H; Hennighausen, K; Clement, HW; Heiser, P; Schulz, E
      Atypical neuroleptics in child and adolescent psychiatry

      EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
    12. Birkett, JT; Arranz, MJ; Munro, J; Osbourn, S; Kerwin, RW; Collier, DA
      Association analysis of the 5-HT5A gene in depression, psychosis and antipsychotic response

      NEUROREPORT
    13. Lauerma, H; Nietosvaara, O; Turunen, M
      Risperidone as an antidote to hallucinogenics - Should it be prescribed?

      HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL
    14. Leopold, NA
      Risperidone treatment of drug-related psychosis in patients with parkinsonism

      MOVEMENT DISORDERS
    15. Kulkarni, SK; Ninan, I
      Dopamine D-4 receptors and development of newer antipsychotic drugs

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    16. Boye, SM; Rompre, PP
      Behavioral evidence of depolarization block of dopamine neurons after chronic treatment with haloperidol and clozapine

      JOURNAL OF NEUROSCIENCE
    17. Meisenzahl, EM; Dresel, S; Frodl, T; Schmitt, GJE; Preuss, UW; Rossmuller, B; Tatsch, K; Mager, T; Hahn, K; Moller, HJ
      D-2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study

      JOURNAL OF PSYCHOPHARMACOLOGY
    18. Pfanner, C; Marazziti, D; Dell'Osso, L; Presta, S; Gemignani, A; Milanfranchi, A; Cassano, GB
      Risperidone augmentation in refractory obsessive-compulsive disorder: an open-label study

      INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
    19. Cosenza, A; Bruni, G; Muratori, F
      VEOS in a six year old girl: Premorbid state, onset, course and therapy

      PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES
    20. Moller, HJ
      Results and methodological problems in the evaluation of newer atypical neuroleptics in the treatment of schizophrenic negative symptoms

      NERVENARZT
    21. Jatzko, A; Ries, S; Schreiner, A; Braus, DF
      Acute tongue and pharyngeal cramps when changing from clozapine to amisupride. A case study

      NERVENARZT
    22. Cussac, D; Newman-Tancredi, A; Nicolas, JP; Boutin, JA; Millan, MJ
      Antagonist properties of the novel antipsychotic, S16924, at cloned, humanserotonin 5-HT2C receptors: a parallel phosphatidylinositol and calcium accumulation comparison with clozapine and haloperidol

      NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
    23. Cusack, B; Boules, M; Tyler, BM; Fauq, A; McCormick, DJ; Richelson, E
      Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol

      BRAIN RESEARCH
    24. Kapur, S; Zipursky, R; Jones, C; Remington, G; Houle, S
      Relationship between dopamine D-2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia

      AMERICAN JOURNAL OF PSYCHIATRY
    25. Moller, HJ
      Amisulpride: a review of its efficacy in schizophrenia

      ACTA PSYCHIATRICA SCANDINAVICA
    26. Montgomery, AMJ; Grottick, AJ; Herberg, LJ
      Rapid recovery of self-stimulation responding from depression by clozapineis prevented by the alpha(2)-adrenoceptor agonist, clonidine

      BEHAVIOURAL PHARMACOLOGY
    27. Moller, HJ
      Atypical neuroleptics: a new approach in the treatment of negative symptoms

      EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
    28. Villemagne, VL; Rothman, RB; Yokoi, F; Rice, KC; Matecka, D; Dannals, RF; Wong, DF
      Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [C-11] WIN35,428 PET scans

      SYNAPSE
    29. Valldeoriola, F; Molinuevo, J
      Therapy of behavioral disorders in Parkinson's disease

      BIOMEDICINE & PHARMACOTHERAPY
    30. Marland, GR
      Atypical neuroleptics: autonomy and compliance?

      JOURNAL OF ADVANCED NURSING
    31. Green, B
      Focus on quetiapine

      CURRENT MEDICAL RESEARCH AND OPINION
    32. Dresel, SHJ; Kung, MP; Huang, XF; Plossl, K; Hou, C; Meegalla, SK; Patselas, G; Mu, M; Saffer, JR; Kung, HF
      Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sitesin baboons

      JOURNAL OF NUCLEAR MEDICINE
    33. Seeman, P; Tallerico, T
      Rapid release of antipsychotic drugs from dopamine D-2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

      AMERICAN JOURNAL OF PSYCHIATRY
    34. SEEMAN P; TALLERICO T
      ANTIPSYCHOTIC-DRUGS WHICH ELICIT LITTLE OR NO PARKINSONISM BIND MORE LOOSELY THAN DOPAMINE TO BRAIN D2 RECEPTORS, YET OCCUPY HIGH-LEVELS OFTHESE RECEPTORS

      Molecular psychiatry
    35. WIRTSHAFTER D
      D-1 DOPAMINE-RECEPTORS MEDIATE NEUROLEPTIC-INDUCED FOS EXPRESSION IN THE ISLANDS OF CALLEJA

      Synapse
    36. LEVINSON AJ; GARSIDE S; ROSEBUSH PI; MAZUREK MF
      HALOPERIDOL INDUCES PERSISTENT DOWN-REGULATION OF TYROSINE-HYDROXYLASE IMMUNOREACTIVITY IN SUBSTANTIA-NIGRA BUT NOT VENTRAL TEGMENTAL AREA IN THE RAT

      Neuroscience
    37. LOKSHIN P; KOTLER M; KUTZUK D; BELMAKER RH
      CLOTIAPINE - AN OLD NEUROLEPTIC WITH POSSIBLE CLOZAPINE-LIKE PROPERTIES

      Progress in neuro-psychopharmacology & biological psychiatry
    38. PARADA MA; DEPARADA MP; HERNANDEZ L; GARCIA F; MURZI E; CONTRERAS Q
      CLOZAPINE-INDUCED ACETYLCHOLINE-RELEASE IN THE RAT PREFRONTAL CORTEX,NUCLEUS-ACCUMBENS AND STRIATUM DOES NOT DEVELOP TOLERANCE

      Progress in neuro-psychopharmacology & biological psychiatry
    39. HANSEN JB; FINKJENSEN A; CHRISTENSEN BV; GRONVALD FC; JEPPESEN L; MOGENSEN JP; NIELSEN EB; SCHEIDELER MA; WHITE FJ; ZHANG XF
      MESOLIMBIC SELECTIVE ANTIPSYCHOTIC ARYLCARBAMATES

      European journal of medicinal chemistry
    40. BROICH K; GRUNWALD F; KASPER S; KLEMM E; BIERSACK HJ; MOLLER HJ
      D-2-DOPAMINE RECEPTOR OCCUPANCY MEASURED BY IBZM-SPECT IN RELATION TOEXTRAPYRAMIDAL SIDE-EFFECTS

      Pharmacopsychiatry
    41. DRESEL S; TATSCH K; DAHNE I; MAGER T; SCHERER J; HAHN K
      IODINE-123-IODOBENZAMIDE SPECT ASSESSMENT OF DOPAMINE D-2 RECEPTOR OCCUPANCY IN RISPERIDONE-TREATED SCHIZOPHRENIC-PATIENTS

      The Journal of nuclear medicine
    42. KIRALY SJ; GIBSON RE; ANCILL RJ; HOLLIDAY SG
      RISPERIDONE - TREATMENT RESPONSE IN ADULT AND GERIATRIC-PATIENTS

      International journal of psychiatry in medicine
    43. DIGIOVANNI G; DIMASCIO M; DIMATTEO V; ESPOSITO E
      EFFECTS OF ACUTE AND REPEATED ADMINISTRATION OF AMISULPRIDE, A DOPAMINE D-2 D-3 RECEPTOR ANTAGONIST, ON THE ELECTRICAL-ACTIVITY OF MIDBRAINDOPAMINERGIC-NEURONS/

      The Journal of pharmacology and experimental therapeutics
    44. MILLAN MJ; GOBERT A; NEWMANTANCREDI A; AUDINOT V; LEJEUNE F; RIVET JM; CUSSAC D; NICOLAS JP; MULLER O; LAVIELLE G
      S-16924 YL]-PYRROLIDIN-3YL)-1-(4-FLUORO-PHENYL)-ETHANONE), A NOVEL POTENTIAL ANTIPSYCHOTIC WITH MARKED SEROTONIN (5-HT)(1A) AGONIST PROPERTIES - I - RECEPTORIAL AND NEUROCHEMICAL PROFILE COMPARISON WITH CLOZAPINE AND HALOPERIDOL

      The Journal of pharmacology and experimental therapeutics
    45. DUNCAN GE; LEIPZIG JN; MAILMAN RB; LIEBERMAN JA
      DIFFERENTIAL-EFFECTS OF CLOZAPINE AND HALOPERIDOL ON KETAMINE-INDUCEDBRAIN METABOLIC-ACTIVATION

      Brain research
    46. LIDOW MS; WILLIAMS GV; GOLDMANRAKIC PS
      THE CEREBRAL-CORTEX - A CASE FOR A COMMON SITE OF ACTION OF ANTIPSYCHOTICS

      Trends in pharmacological sciences
    47. ROE DL; BARDGETT ME; CSERNANSKY CA; CSERNANSKY JG
      INDUCTION OF FOS PROTEIN BY ANTIPSYCHOTIC-DRUGS IN RAT-BRAIN FOLLOWING KAINIC ACID-INDUCED LIMBIC-CORTICAL NEURONAL LOSS

      Psychopharmacology
    48. LI XM; PERRY KW; WONG DT; BYMASTER FP
      OLANZAPINE INCREASES IN-VIVO DOPAMINE AND NOREPINEPHRINE RELEASE IN RAT PREFRONTAL CORTEX, NUCLEUS-ACCUMBENS AND STRIATUM

      Psychopharmacology
    49. ZHANG XX; SUN BC; JIN GZ
      ATYPICAL NEUROLEPTIC PROPERTIES OF L-STEPHOLIDINE

      SCIENCE IN CHINA SERIES C-LIFE SCIENCES
    50. SAMSDODD F
      EFFECT OF NOVEL ANTIPSYCHOTIC-DRUGS ON PHENCYCLIDINE-INDUCED STEREOTYPED BEHAVIOR AND SOCIAL-ISOLATION IN THE RAT SOCIAL-INTERACTION TEST

      Behavioural pharmacology
    51. SCHERER J; TATSCH K; ALBUS M; SCHWARZ J; MAGER T; OERTEL WH
      D-2-DOPAMINE-RECEPTOR OCCUPANCY DURING TREATMENT WITH HALOPERIDOL DECANOATE

      European archives of psychiatry and clinical neuroscience
    52. KNABLE MB; HEINZ A; RAEDLER T; WEINBERGER DR
      EXTRAPYRAMIDAL SIDE-EFFECTS WITH RISPERIDONE AND HALOPERIDOL AT COMPARABLE D2 RECEPTOR OCCUPANCY LEVELS

      PSYCHIATRY RESEARCH-NEUROIMAGING
    53. KOSTEN TA
      ENHANCED NEUROBEHAVIORAL EFFECTS OF COCAINE WITH CHRONIC NEUROLEPTIC EXPOSURE IN RATS

      Schizophrenia bulletin
    54. ROTHBLAT DS; SCHNEIDER JS
      REGIONALLY SPECIFIC EFFECTS OF HALOPERIDOL AND CLOZAPINE ON DOPAMINE REUPTAKE IN THE STRIATUM

      Neuroscience letters
    55. SCHREIBER S; BACKER MM; WEIZMAN R; PICK CG
      AUGMENTATION OF OPIOID-INDUCED ANTINOCICEPTION BY THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE IN MICE

      Neuroscience letters
    56. RAMMSAYER TH
      ARE THERE DISSOCIABLE ROLES OF THE MESOSTRIATAL AND MESOLIMBOCORTICALDOPAMINE SYSTEMS ON TEMPORAL INFORMATION-PROCESSING IN HUMANS

      Neuropsychobiology
    57. ARNT J; SKARSFELDT T; HYTTEL J
      DIFFERENTIATION OF CLASSICAL AND NOVEL ANTIPSYCHOTICS USING ANIMAL-MODELS

      International clinical psychopharmacology
    58. HUANG NN; ASE AR; HEBERT C; VANGELDER NM; READER TA
      EFFECTS OF CHRONIC NEUROLEPTIC TREATMENTS ON DOPAMINE D-1 AND D-2 RECEPTORS - HOMOGENATE BINDING AND AUTORADIOGRAPHIC STUDIES

      Neurochemistry international
    59. MONTELEONE P; FABRAZZO M; TORTORELLA A; MAJ M
      PLASMA-LEVELS OF INTERLEUKIN-6 AND TUMOR-NECROSIS-FACTOR-ALPHA IN CHRONIC-SCHIZOPHRENIA - EFFECTS OF CLOZAPINE TREATMENT

      Psychiatry research
    60. GROTTICK AJ; MONTGOMERY AMJ; HERBERG LJ
      RAPID RECOVERY OF SELF-STIMULATION FROM DEPRESSION PRODUCED BY THE ATYPICAL NEUROLEPTIC RISPERIDONE IS NOT PREVENTED BY 5-HT2 RECEPTOR STIMULATION

      Pharmacology, biochemistry and behavior
    61. FELDMAN DJ; FRANK RA; KEHNE JH; FLANNERY R; BROWN D; SONI S; BYRD G; SHAH S
      MIXED D-2 5-HT2 ANTAGONISM DIFFERENTIALLY AFFECTS APOMORPHINE-INDUCEDAND AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR/

      Pharmacology, biochemistry and behavior
    62. MORTIMER AM
      COGNITIVE FUNCTION IN SCHIZOPHRENIA - DO NEUROLEPTICS MAKE A DIFFERENCE

      Pharmacology, biochemistry and behavior
    63. MEIL WM; SCHECHTER MD
      OLANZAPINE ATTENUATES THE REINFORCING EFFECTS OF COCAINE

      European journal of pharmacology
    64. STEVENS JR; DENNEY D; SZOT P
      SENSITIZATION WITH CLOZAPINE - BEYOND THE DOPAMINE HYPOTHESIS

      Biological psychiatry
    65. BARDGETT ME; SALARIS SL; JACKSON JL; HARDING J; CSERNANSKY JG
      THE EFFECTS OF KAINIC ACID LESIONS ON DOPAMINERGIC RESPONSES TO HALOPERIDOL AND CLOZAPINE

      Psychopharmacology
    66. KUFFERLE B; BRUCKE T; TOPITZSCHRATZBERGER A; TAUSCHER J; GOSSLER R; VESELY C; ASENBAUM S; PODREKA I; KASPER S
      STRIATAL DOPAMINE-2 RECEPTOR OCCUPANCY IN PSYCHOTIC-PATIENTS TREATED WITH RISPERIDONE

      PSYCHIATRY RESEARCH-NEUROIMAGING
    67. VANELLE JM; BROCHIER T; BAYLE FJ; LOO H
      ATYPICAL NEUROLEPTICS - THEIR CONTRIBUTION TO THE REHABILITATION OF SCHIZOPHRENIC-PATIENTS

      European psychiatry
    68. STEVENS JR; DENNEY D; SZOT P
      KINDLING WITH CLOZAPINE - BEHAVIORAL AND MOLECULAR CONSEQUENCES

      Epilepsy research
    69. ERICSON H; RADESATER AC; SERVIN E; MAGNUSSON O; MOHRINGE B
      EFFECTS OF INTERMITTENT AND CONTINUOUS SUBCHRONIC ADMINISTRATION OF RACLOPRIDE ON MOTOR-ACTIVITY, DOPAMINE TURNOVER AND RECEPTOR OCCUPANCY IN THE RAT

      Pharmacology & toxicology
    70. STIP E
      MEMORY IMPAIRMENT IN SCHIZOPHRENIA - PERSPECTIVES FROM PSYCHOPATHOLOGY AND PHARMACOTHERAPY

      Canadian journal of psychiatry
    71. STIP E; LUSSIER I
      THE EFFECT OF RISPERIDONE ON COGNITION IN PATIENTS WITH SCHIZOPHRENIA

      Canadian journal of psychiatry
    72. BEDARD MA; SCHERER H; DELORIMIER J; STIP E; LALONDE P
      DIFFERENTIAL-EFFECTS OF D-2-BLOCKING AND D-4-BLOCKING NEUROLEPTICS ONTHE PROCEDURAL LEARNING OF SCHIZOPHRENIC-PATIENTS

      Canadian journal of psychiatry
    73. ALLEN SM; RICE SN
      RISPERIDONE ANTAGONISM OF SELF-MUTILATION IN A LESCH-NYHAN PATIENT

      Progress in neuro-psychopharmacology & biological psychiatry
    74. HEINZ A; KNABLE MB; WEINBERGER DR
      DOPAMINE D-2 RECEPTOR IMAGING AND NEUROLEPTIC DRUG RESPONSE

      The Journal of clinical psychiatry
    75. EGAN MF; FERGUSON J; HYDE TM
      EFFECTS OF RATING PARAMETERS ON ASSESSMENT OF NEUROLEPTIC-INDUCED VACUOUS CHEWING MOVEMENTS

      Pharmacology, biochemistry and behavior
    76. SMALL JG; KLAPPER MH; MILSTEIN V; MARHENKE JD; SMALL IF
      COMPARISON OF THERAPEUTIC MODALITIES FOR MANIA

      Psychopharmacology bulletin
    77. SCHLICKER E; MARR I
      THE MODERATE AFFINITY OF CLOZAPINE AT H-3 RECEPTORS IS NOT SHARED BY ITS 2 MAJOR METABOLITES AND BY STRUCTURALLY RELATED AND UNRELATED ATYPICAL NEUROLEPTICS

      Naunyn-Schmiedeberg's archives of pharmacology
    78. SMITH RC; KADEWARI RP
      NEUROLOGICAL SOFT SIGNS AND RESPONSE TO RISPERIDONE IN CHRONIC-SCHIZOPHRENIA

      Biological psychiatry
    79. SMALL JG; MILSTEIN V; MALLOY FW; MILLER MJ
      QUANTITATIVE ELECTROENCEPHALOGRAPHIC FREQUENCIES AND RELATIVE NEUROLEPTIC RECEPTOR AFFINITIES IN SCHIZOPHRENIA

      Biological psychiatry
    80. PICKAR D; SU TP; WEINBERGER DR; COPPOLA R; MALHOTRA AK; KNABLE MB; LEE KS; GOREY J; BARTKO JJ; BREIER A; HSIAO J
      INDIVIDUAL VARIATION IN D-2 DOPAMINE-RECEPTOR OCCUPANCY IN CLOZAPINE-TREATED PATIENTS

      The American journal of psychiatry
    81. HURLEY MJ; STUBBS CM; JENNER P; MARSDEN CD
      EFFECT OF CHRONIC TREATMENT WITH TYPICAL AND ATYPICAL NEUROLEPTICS ONTHE EXPRESSION OF DOPAMINE D-2 AND D-3 RECEPTORS IN RAT-BRAIN

      Psychopharmacology
    82. KOSTEN TA; DECAPRIO JL; NESTLER EJ
      LONG-TERM HALOPERIDOL ADMINISTRATION ENHANCES AND SHORT-TERM ADMINISTRATION ATTENUATES THE BEHAVIORAL-EFFECTS OF COCAINE IN A PLACE CONDITIONING PROCEDURE

      Psychopharmacology
    83. BYMASTER FP; HEMRICKLUECKE SK; PERRY KW; FULLER RW
      NEUROCHEMICAL EVIDENCE FOR ANTAGONISM BY OLANZAPINE OF DOPAMINE, SEROTONIN, ALPHA(1)-ADRENERGIC AND MUSCARINIC RECEPTORS IN-VIVO IN RATS

      Psychopharmacology
    84. HACKSELL U; JACKSON DM; MOHELL N
      DOES THE DOPAMINE-RECEPTOR SUBTYPE SELECTIVITY OF ANTIPSYCHOTIC AGENTS PROVIDE USEFUL LEADS FOR THE DEVELOPMENT OF NOVEL THERAPEUTIC AGENTS

      Pharmacology & toxicology
    85. FERRE S; ARTIGAS F
      CLOZAPINE DECREASES SEROTONIN EXTRACELLULAR LEVELS IN THE NUCLEUS-ACCUMBENS BY A DOPAMINE RECEPTOR-INDEPENDENT MECHANISM

      Neuroscience letters
    86. KAKIGI T; GAO XM; TAMMINGA CA
      DRUG-INDUCED ORAL DYSKINESIAS IN RATS AFTER TRADITIONAL AND NEW NEUROLEPTICS

      Journal of neural transmission
    87. DORAISWAMY M; MARTIN W; METZ A; DEVEAUGHGEISS J
      PSYCHOSIS IN PARKINSONS-DISEASE - DIAGNOSIS AND TREATMENT

      Progress in neuro-psychopharmacology & biological psychiatry
    88. UNIS AS; VINCENT JG; DILLON B
      DOPAMINE D-2 RECEPTOR AUTORADIOGRAPHY WITH [H-3] YM-09151-2 REFLECTS BRAIN AND BEHAVIORAL ONTOGENY

      Progress in neuro-psychopharmacology & biological psychiatry
    89. FITZGERALD LW; DEUTCH AY; GASIC G; HEINEMANN SF; NESTLER EJ
      REGULATION OF CORTICAL AND SUBCORTICAL GLUTAMATE-RECEPTOR SUBUNIT EXPRESSION BY ANTIPSYCHOTIC-DRUGS

      The Journal of neuroscience
    90. HERBERG LJ; MONTGOMERY AMJ; GROTTICK AJ
      ALPHA(2)-ADRENOCEPTOR ANTAGONISM MAY CONTRIBUTE TO THE ATYPICAL PROPERTIES OF RISPERIDONE - EXPERIMENTAL SUPPORT FOR THE NUTT CASE

      JOURNAL OF PSYCHOPHARMACOLOGY
    91. SCURLOCK HJ; SINGH AN; CATALAN J
      ATYPICAL ANTIPSYCHOTIC-DRUGS IN THE TREATMENT OF MANIC SYNDROMES IN PATIENTS WITH HIV-1 INFECTION

      JOURNAL OF PSYCHOPHARMACOLOGY
    92. BALDWIN DS; MONTGOMERY SA
      FIRST CLINICAL-EXPERIENCE WITH OLANZAPINE (LY-170053) - RESULTS OF ANOPEN-LABEL SAFETY AND DOSE-RANGING STUDY IN PATIENTS WITH SCHIZOPHRENIA

      International clinical psychopharmacology
    93. BARDGETT ME; JACKSON JL; TAYLOR GT; CSERNANSKY JG
      KAINIC ACID DECREASES HIPPOCAMPAL NEURONAL NUMBER AND INCREASES DOPAMINE-RECEPTOR BINDING IN THE NUCLEUS-ACCUMBENS - AN ANIMAL-MODEL OF SCHIZOPHRENIA

      Behavioural brain research
    94. DASSA D; NAUDIN J; AZORIN JM
      ATYPICAL NEUROLEPTICS AND NEW PATTERNS FO R PSYCHOSES

      Annales medico-psychologiques
    95. COOLS AR; PRINSSEN EPM; ELLENBROEK BA
      THE OLFACTORY TUBERCLE AS A SITE OF ACTION OF NEUROLEPTICS WITH AN ATYPICAL PROFILE IN THE PAW TEST - EFFECT OF RISPERIDONE, PROTHIPENDYL, ORG-5222, SERTINDOLE AND OLANZAPINE

      Psychopharmacology
    96. WETZEL H; SZEGEDI A; HAIN C; WIESNER J; SCHLEGEL S; BENKERT O
      SEROQUEL (ICI-204-636), A PUTATIVE ATYPICAL ANTIPSYCHOTIC, IN SCHIZOPHRENIA WITH POSITIVE SYMPTOMATOLOGY - RESULTS OF AN OPEN CLINICAL-TRIAL AND CHANGES OF NEUROENDOCRINOLOGICAL AND EEG PARAMETERS

      Psychopharmacology
    97. ELLENBROEK BA; PRINSSEN EPM; COOLS AR
      THE ROLE OF SEROTONIN RECEPTOR SUBTYPES IN THE BEHAVIORAL-EFFECTS OF NEUROLEPTIC DRUGS - A PAW TEST STUDY IN RATS

      European journal of neuroscience
    98. RADHAKISHUN FS; WESTERINK BHC; STOOF JC; WOLTERINK G; VANREE JM
      SUBCHRONIC TREATMENT WITH THE NEUROLEPTIC-LIKE PEPTIDE DESENKEPHALIN-GAMMA-ENDORPHIN MAY DECREASE DOPAMINERGIC NEUROTRANSMISSION IN THE NUCLEUS-ACCUMBENS OF RATS

      European neuropsychopharmacology
    99. SIGMUNDSON HK
      PHARMACOTHERAPY OF SCHIZOPHRENIA - A REVIEW

      Canadian journal of psychiatry
    100. RAO ML; MOLLER HJ
      BIOCHEMICAL FINDINGS OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA AND THEIR PUTATIVE RELEVANCE TO PHARMACOLOGICAL TREATMENT - A REVIEW

      Neuropsychobiology


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 12:05:15